Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
- PMID: 9261346
- PMCID: PMC191902
- DOI: 10.1128/JVI.71.9.6296-6304.1997
Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
Abstract
Several members of the chemokine receptor family have recently been identified as coreceptors, with CD4, for entry of human immunodeficiency virus type 1 (HIV-1) into target cells. In this report, we show that the envelope glycoproteins of several strains of HIV-2 and simian immunodeficiency virus (SIV) employ the same chemokine receptors for infection. Envelope glycoproteins from HIV-2 use CCR5 or CXCR4, while those from several strains of SIV use CCR5. Our data indicate also that some viral envelopes can use more than one coreceptor for entry and suggest that some of these coreceptors remain to be identified. To further understand how different envelope molecules use CCR5 as an entry cofactor, we show that soluble purified envelope glycoproteins (SU component) from CCR5-tropic HIV-1, HIV-2, and SIV can compete for binding of iodinated chemokine to CCR5. The competition is dependent on binding of the SU glycoprotein to cell surface CD4 and implies a direct interaction between envelope glycoproteins and CCR5. This interaction is specific since it is not observed with SU glycoprotein from a CXCR4-tropic virus or with a chemokine receptor that is not competent for viral entry (CCR1). For HIV-1, the interaction can be inhibited by antibodies specific for the V3 loop of SU. Soluble CD4 was found to potentiate binding of the HIV-2 ST and SIVmac239 envelope glycoproteins to CCR5, suggesting that a CD4-induced conformational change in SU is required for subsequent binding to CCR5. These data suggest a common fundamental mechanism by which structurally diverse HIV-1, HIV-2, and SIV envelope glycoproteins interact with CD4 and CCR5 to mediate viral entry.
Similar articles
-
Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins.Virology. 1998 Sep 30;249(2):367-78. doi: 10.1006/viro.1998.9306. Virology. 1998. PMID: 9791028
-
Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.J Virol. 2002 Nov;76(21):10627-36. doi: 10.1128/jvi.76.21.10627-10636.2002. J Virol. 2002. PMID: 12368305 Free PMC article.
-
Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.J Virol. 1997 Dec;71(12):8999-9007. doi: 10.1128/JVI.71.12.8999-9007.1997. J Virol. 1997. PMID: 9371556 Free PMC article.
-
[Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].Acta Med Port. 2008 Sep-Oct;21(5):497-504. Epub 2009 Jan 16. Acta Med Port. 2008. PMID: 19187693 Review. Portuguese.
-
Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors.Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):219-43. doi: 10.1016/s1359-6101(00)00033-2. Cytokine Growth Factor Rev. 2001. PMID: 11325604 Review.
Cited by
-
Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.J Virol. 2007 May;81(10):5331-8. doi: 10.1128/JVI.02789-06. Epub 2007 Feb 14. J Virol. 2007. PMID: 17301136 Free PMC article.
-
Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Virology. 2010 Sep 30;405(2):513-23. doi: 10.1016/j.virol.2010.06.027. Epub 2010 Jul 21. Virology. 2010. PMID: 20663531 Free PMC article.
-
Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.J Virol. 2001 Nov;75(21):10200-7. doi: 10.1128/JVI.75.21.10200-10207.2001. J Virol. 2001. PMID: 11581388 Free PMC article.
-
Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.J Virol. 1999 Jan;73(1):684-94. doi: 10.1128/JVI.73.1.684-694.1999. J Virol. 1999. PMID: 9847374 Free PMC article.
-
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.J Virol. 2002 Sep;76(18):9035-45. doi: 10.1128/jvi.76.18.9035-9045.2002. J Virol. 2002. PMID: 12186887 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials